He leads the Prostate Cancer Translational Research lab at Vall Hebron Institute of Oncology in Barcelona. After completing medical school and clinical training in Medical Oncology, he joined the The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011, where he pursued his PhD in Prof. Johann de Bono´s laboratory, developing first-in-man clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway, with particular interest in developing novel therapies for prostate cancer patients in parallel to developing predictive biomarkers for a more genomics-tailored patient care. His main interest is the integration of tumor molecular characterisation data into real-time clinical decision-making for patients through multidisciplinary tumor boards.